Search Results
Sep 08, 2026, 07:05 ET REGENXBIO to Participate in Upcoming Investor Conferences
of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients
More news about: REGENXBIO Inc.
Sep 03, 2026, 09:15 ET AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma
careNORTH CHICAGO, Ill., Sept. 3, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced positive topline results from the Phase 3 CERVINO study1 evaluating etentamig, an investigational BCMA x CD3 bispecific T-cell
More news about: AbbVie
Sep 03, 2026, 08:34 ET AbbVie Completes Acquisition of Apogee Therapeutics
$3.88NORTH CHICAGO, Ill., Sept. 3, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Apogee Therapeutics, Inc. (NASDAQ: APGE). With completion of the acquisition, Apogee is now
More news about: AbbVie
Sep 03, 2026, 08:05 ET AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
NORTH CHICAGO, Ill., Sept. 3, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026. Management will participate in a fireside
More news about: AbbVie
Sep 01, 2026, 11:37 ET A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture
Inc. (Nasdaq: CNXU), Establishment Labs Holdings Inc. (NASDAQ: ESTA), Evolus, Inc. (NASDAQ: EOLS), InMode Ltd. (NASDAQ: INMD), and AbbVie Inc. (NYSE: ABBV).
More news about: Equity Insider
Sep 01, 2026, 08:05 ET SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings
IRVINE, Calif., Sept. 1, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), expands SkinMedica's portfolio of regenerative skincare products with the launch of Barrier Calming Cream. The restorative moisturizer is designed
More news about: AbbVie
Aug 31, 2026, 08:00 ET AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference
NORTH CHICAGO, Ill., Aug. 31, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026. Management will participate in a fireside chat at
More news about: AbbVie
Aug 27, 2026, 02:00 ET AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
inductionNORTH CHICAGO, Ill., Aug. 27, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted an application to the European Medicines Agency (EMA) seeking approval for SKYRIZI® (risankizumab)
More news about: AbbVie
Aug 25, 2026, 07:05 ET REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie, and RGX-121(clemidsogene lanparvovec) for the treatment of
More news about: REGENXBIO Inc.
Aug 24, 2026, 07:05 ET REGENXBIO Announces Regulatory Update on RGX-121 for MPS II
late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie, and RGX-121 (clemidsogene lanparvovec) for the treatment of
More news about: REGENXBIO Inc.
Aug 21, 2026, 07:45 ET AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline
Clinical data from AbbVie's ABBV-1480 (RC148) PD-1/VEGF bispecific antibody in the frontline non-small cell lung cancer (NSCLC) setting will be presented via an oral presentationAdditionally, new data and updates from AbbVie's telisotuzumab adizutecan (Temab-A) and ABBV-706 programs across NSCLC
More news about: AbbVie
Aug 18, 2026, 08:00 ET AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support
NORTH CHICAGO, Ill., Aug. 18, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced 34 students living with inflammatory conditions across dermatology, gastroenterology and rheumatology will receive the 2026 AbbVie Immunology
More news about: AbbVie
Aug 10, 2026, 10:31 ET Major Depressive Disorder Market is Predicted to Grow During the Forecast Period (2026-2036) as Novel Antidepressants are Expected to Enter the Market | DelveInsight
disorder therapies in clinical trials include Seltorexant, Azetukalner, Itruvone (PH10), HLP003, Osavampator, Brenipatide, Bretisilocin, Icalcaprant (ABBV-1354), Elunetirom (ABX-002), DT120, Zelquistinel, Forvisirvat (SP-624), ALTO-300, GlyphAllo (SPT-300), and others.Discover what medications
More news about: DelveInsight Business Research, LLP
Aug 06, 2026, 07:05 ET REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
dystrophy on track for Q3 2026 initiation, with potential accelerated approval in 2H 2027Long-term surabgene lomparvovec (sura-vec, ABBV-RGX-314) data highlight durable safety and efficacy profile ahead of key catalystTopline data from pivotal subretinal wet AMD
More news about: REGENXBIO Inc.
Aug 04, 2026, 08:00 ET Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence
IRVINE, Calif., Aug. 4, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for BOTOX® Cosmetic
More news about: AbbVie
Aug 03, 2026, 09:00 ET BOTOX® (toxina botulínica A) recebe aprovação da Anvisa para uso no músculo platisma
SÃO PAULO, 3 de agosto de 2026 /PRNewswire/ -- A Allergan Aesthetics, uma empresa AbbVie (NYSE: ABBV), anuncia que a Agência Nacional de Vigilância Sanitária (Anvisa) aprovou o uso de BOTOX® (toxina botulínica A) para a melhora da aparência
More news about: Allergan
Aug 03, 2026, 08:00 ET cAMPfield Strengthens Leadership Team with Key Executive Appointments, Including Graham Heap, MD, PhD as President, R&D, to Advance Prifemilast into Global Phase 2 Development for Inflammatory Bowel Disease
programs with adalimumab and risankizumab. He most recently served as Head of Asset/Indication for Skyrizi®, Humira®, ABBV-547, and ABBV-423, and is a physician-scientist trained in gastroenterology and hepatology.Taylor Spector, PhD – Executive Director, Head of Medical
More news about: cAMPfield Therapeutics
Aug 03, 2026, 07:05 ET REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights
late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie, and NAVSUNLI™ (clemidsogene lanparvovec-sngl, RGX-121) for
More news about: REGENXBIO Inc.
Jul 31, 2026, 07:47 ET AbbVie Reports Second-Quarter 2026 Financial Results
cancers. Featured data from AbbVie's blood cancer portfolio and pipeline included 21 oral and poster presentations, which highlighted etentamig (ABBV-383), Epkinly and Decnupaz. The presentations also showcased Venclexta (venetoclax) data, including a final analysis of the Phase 3 CLL14 trial which demonstrated
More news about: AbbVie
Jul 30, 2026, 10:31 ET Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight
TEV-574 (duvakitug), AGMB-129, Olamkicept, JNJ-4804 Co-antibody Therapy, Zotemtegrast, ATH-063, SPY001, SPY002, SPY003, DB-3Q, Zasocitinib, ABBV-243, ABBV-701, TRX103, XmAb412, and others.Discover what is the effectiveness of Johnson & Johnson's medications for managing symptoms
More news about: DelveInsight Business Research, LLP
Jul 30, 2026, 08:00 ET JUVÉDERM® Day Returns to U.S. on August 19
NORTH CHICAGO, Ill., July 30, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the return of
More news about: AbbVie
Jul 29, 2026, 03:00 ET AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo
placebo1NORTH CHICAGO, Ill., July 29, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment of adult and adolescent
More news about: AbbVie
Jul 29, 2026, 03:00 ET AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
24NORTH CHICAGO, Ill., July 29, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib; 15 mg and 30 mg, once daily) for the treatment of adult
More news about: AbbVie
Jul 18, 2026, 14:55 ET REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting
REGENXBIO Inc. (Nasdaq: RGNX) today announced positive data from long-term follow-up studies of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in wet AMD using subretinal delivery and diabetic retinopathy (DR) using suprachoroidal delivery. These new data were presented at the American
More news about: REGENXBIO Inc.
Jul 17, 2026, 08:00 ET Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
NORTH CHICAGO, Ill., July 17, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the European Commission has approved Boey® (trenibotulinumtoxinE) in Europe, for the temporary improvement in the appearance of
More news about: AbbVie